Repligen Corp
Company Profile
Business description
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Contact
41 Seyon Street
Building 1, Suite 100
WalthamMA02453
USAT: +1 781 250-0111
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
1,778
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,293.20 | 45.10 | -0.48% |
| CAC 40 | 8,174.20 | 14.39 | -0.18% |
| DAX 40 | 23,830.99 | 441.20 | -1.82% |
| Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
| FTSE 100 | 9,354.57 | 81.52 | -0.86% |
| HKSE | 25,247.10 | 641.41 | -2.48% |
| NASDAQ | 22,679.97 | 117.44 | 0.52% |
| Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,664.01 | 34.94 | 0.53% |
| S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
| SSE Composite Index | 3,839.76 | 76.47 | -1.95% |